homepage-top-section

Exscientia has expanded its partnership with Bristol-Myers Squibb (BMS) to leverage artificial intelligence (AI) to discover small molecule drug candidates across oncology and immunology, among other therapeutic areas.

As part of the agreement, BMS will pay $200m upfront to Agenus, which is also eligible for up to $1.36bn in development, regulatory and commercial milestone payments and

The agreement also covers additional payments of up to $57.5m contingent on future performance. Charles River expects the deal to boost its gene therapy capabilities for viral vectors

The Central Drugs Laboratory cleared the first batch of Sputnik V doses that reached India earlier this month. Under the pilot, a soft launch has begun, and the

Besides acquiring the exclusive rights to commercialise PRG1801 in India, Dr. Reddy’s will be responsible for future development including clinical trials, in the country. Pregene will be the sole supplier

The Russian Direct Investment Fund (RDIF) has announced that a single dose Covid-19 vaccine called Sputnik Light, obtained authorisation for use in the country. With recombinant human adenovirus

Pfizer Canada and BioNTech have received Interim Order authorisation from Health Canada for the use of their Covid-19 vaccine in adolescents aged 12 to 15 years. This Covid-19

World Health Organization (WHO) has granted emergency use listing (EUL) for Moderna’s Covid-19 vaccine to prevent the infection in people aged 18 years and above. The Covid-19 Vaccine

Pharmaceutical company Pfizer has acquired  a privately held company Amplyx Pharmaceuticals for an undisclosed amount. Amplyx is developing treatment for life-threatening diseases caused due to failing immune system.